Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 28, 2011 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma Announces Clinical Development Collaboration With Genentech/Roche and The Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF) for NeuVax(TM) (E75) Combined With Herceptin(R) (trastuzumab) in Adjuvant Breast Cancer

Randomized Phase 2 clinical study in 300 patients for adjuvant breast cancer to commence in 1H, 2012. Additional clinical study expands potential uses for NeuVax™ in combination...
November 18, 2011 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma Announces NeuVax(TM) Poster Presentations at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium

LAKE OSWEGO, Ore., Nov. 18, 2011 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE), a biotechnology company focused on developing innovative, targeted oncology treatments addressing major unmet...
November 14, 2011 16:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma Reports Third Quarter 2011 Financial Results and Provides Business Update

NeuVax™ (E75) makes significant progress towards initiating the Phase 3 PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2...
November 08, 2011 11:17 ET | Source: Galena Biopharma, Inc.

Galena Biopharma to Present at the Lazard Capital Markets 8th Annual Healthcare Conference

LAKE OSWEGO, Ore., Nov. 8, 2011 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE), a biotechnology company focused on developing innovative, targeted oncology treatments that address major unmet...
November 04, 2011 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma Presents Positive NeuVax(TM) Clinical Results at the 26th Annual Meeting of the Society for Immunotherapy of Cancer

LAKE OSWEGO, Ore., Nov. 4, 2011 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE), a biotechnology company focused on developing innovative, targeted oncology treatments that address major unmet...
October 26, 2011 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma to Present Updated NeuVax(TM) Clinical Results at the 26th Annual Meeting of the Society for the Immunotherapy of Cancer

LAKE OSWEGO, Ore., Oct. 26, 2011 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE), a biotechnology company focused on developing innovative, targeted oncology treatments that address major unmet...
October 25, 2011 12:18 ET | Source: Galena Biopharma, Inc.

Galena Biopharma Accelerates Strategy to Focus on Late Stage Targeted Cancer Drug Development

Galena Biopharma submits SEC filing for spin-off of non-core RNAi assets. Galena will retain a 4% equity position, with the potential to receive up to $45 million in milestones; and...
October 21, 2011 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma to Present at the 10th Annual Biotechnology Investor Forum

LAKE OSWEGO, Ore., Oct. 21, 2011 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:RXII), a biotechnology company focused on developing innovative, targeted oncology treatments that address major unmet...
October 20, 2011 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma's NeuVax (E75) Clinical Trial Results Published in Cancer

PORTLAND, Ore., Oct. 20, 2011 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:RXII), a biotechnology company focused on developing innovative, targeted oncology treatments that address major unmet...
October 05, 2011 07:05 ET | Source: Galena Biopharma, Inc.

Galena Biopharma to Present at the 2nd Annual Cancer Immunotherapy: A Long-Awaited Reality Conference

LAKE OSWEGO, Ore., Oct. 5, 2011 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:RXII), a biotechnology company focused on developing innovative, targeted oncology treatments that address major unmet...